GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (NAS:EQ) » Definitions » Beneish M-Score

Equillium (Equillium) Beneish M-Score : -0.82 (As of May. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Equillium Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.82 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Equillium's Beneish M-Score or its related term are showing as below:

EQ' s Beneish M-Score Range Over the Past 10 Years
Min: -0.82   Med: -0.82   Max: -0.82
Current: -0.82

During the past 7 years, the highest Beneish M-Score of Equillium was -0.82. The lowest was -0.82. And the median was -0.82.


Equillium Beneish M-Score Historical Data

The historical data trend for Equillium's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Beneish M-Score Chart

Equillium Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - - - -0.82

Equillium Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -0.82

Competitive Comparison of Equillium's Beneish M-Score

For the Biotechnology subindustry, Equillium's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Equillium's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Equillium's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Equillium's Beneish M-Score falls into.



Equillium Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Equillium for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.6675+0.528 * 1+0.404 * 1.0445+0.892 * 2.2897+0.115 * 0.6815
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.3437+4.679 * 0.168692-0.327 * 1.2019
=-0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $6.29 Mil.
Revenue was 9.211 + 8.87 + 9.124 + 8.879 = $36.08 Mil.
Gross Profit was 9.211 + 8.87 + 9.124 + 8.879 = $36.08 Mil.
Total Current Assets was $49.35 Mil.
Total Assets was $50.53 Mil.
Property, Plant and Equipment(Net PPE) was $1.11 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.13 Mil.
Selling, General, & Admin. Expense(SGA) was $13.57 Mil.
Total Current Liabilities was $27.57 Mil.
Long-Term Debt & Capital Lease Obligation was $0.38 Mil.
Net Income was -2.342 + -3.71 + -3.343 + -3.94 = $-13.34 Mil.
Non Operating Income was 0.357 + -0.142 + -0.112 + -0.179 = $-0.08 Mil.
Cash Flow from Operations was -5.664 + -1.909 + -6.215 + -7.995 = $-21.78 Mil.
Total Receivables was $4.11 Mil.
Revenue was 15.759 + 0 + 0 + 0 = $15.76 Mil.
Gross Profit was 15.759 + 0 + 0 + 0 = $15.76 Mil.
Total Current Assets was $76.74 Mil.
Total Assets was $78.42 Mil.
Property, Plant and Equipment(Net PPE) was $1.58 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.12 Mil.
Selling, General, & Admin. Expense(SGA) was $17.24 Mil.
Total Current Liabilities was $32.04 Mil.
Long-Term Debt & Capital Lease Obligation was $4.06 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(6.286 / 36.084) / (4.113 / 15.759)
=0.174205 / 0.260994
=0.6675

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(15.759 / 15.759) / (36.084 / 36.084)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (49.349 + 1.111) / 50.53) / (1 - (76.735 + 1.582) / 78.421)
=0.001385 / 0.001326
=1.0445

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=36.084 / 15.759
=2.2897

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.118 / (0.118 + 1.582)) / (0.126 / (0.126 + 1.111))
=0.069412 / 0.101859
=0.6815

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(13.566 / 36.084) / (17.239 / 15.759)
=0.375956 / 1.093915
=0.3437

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.384 + 27.573) / 50.53) / ((4.063 + 32.038) / 78.421)
=0.553275 / 0.460349
=1.2019

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-13.335 - -0.076 - -21.783) / 50.53
=0.168692

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Equillium has a M-score of -0.82 signals that the company is likely to be a manipulator.


Equillium Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Equillium's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Equillium (Equillium) Business Description

Traded in Other Exchanges
Address
2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Executives
Jason A Keyes officer: Chief Financial Officer 3344 NORTH TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Barbara Troupin director C/O EQUILLIUM, INC., 2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Christine Zedelmayer officer: Sr. Vice President and COO 2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Stephen Connelly director, officer: Chief Scientific Officer 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Decheng Capital Management Iv (cayman), Llc 10 percent owner P.O. BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Decheng Capital Global Life Sciences Fund Iv, L.p. 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, P.O. BOX 309, GRAND CAYMAN E9 KY1-1104
Xiangmin Cui 10 percent owner NO. 14 EAST HUSHAN ROAD, TAI'AN CITY, SHANDONG F4 000000
Yu (katherine) Xu director P.O. BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Joel Rothman officer: Chief Development Officer 2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Dolca Thomas officer: Chief Medical Officer C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bala S Manian director 1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Charles Douglas Mcdermott director 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Krishna R Polu officer: Chief Medical Officer C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Sa Biocon 10 percent owner CO BDO SA, RUE DE LAVENIR 2, DELEMONT V8 2800
Bruce D. Steel director, officer: President, CBO C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555